Cargando…

Celiac disease among at-risk individuals in Saudi Arabia

OBJECTIVES: To perform a meta-analysis for celiac diseases (CD) among at-risk populations in Kingdom of Saudi Arabia (KSA), as well as a comparison with our previously reported meta-analysis in the normal population. METHODS: In March 2018, at King Abdulaziz University, Jeddah, KSA we commenced a re...

Descripción completa

Detalles Bibliográficos
Autor principal: Safi, Mohammad-Ayman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452613/
https://www.ncbi.nlm.nih.gov/pubmed/30617375
http://dx.doi.org/10.15537/smj.2019.1.23892
_version_ 1783409326324449280
author Safi, Mohammad-Ayman A.
author_facet Safi, Mohammad-Ayman A.
author_sort Safi, Mohammad-Ayman A.
collection PubMed
description OBJECTIVES: To perform a meta-analysis for celiac diseases (CD) among at-risk populations in Kingdom of Saudi Arabia (KSA), as well as a comparison with our previously reported meta-analysis in the normal population. METHODS: In March 2018, at King Abdulaziz University, Jeddah, KSA we commenced a retrospective comprehensive database and journal search for CD among at-risk populations in SA. Data from each of the relevant articles were analyzed using the Statistical Package for Social Science Version 20 (Armonk, NY: IBM Corp.). and the comprehensive meta-analysis program (CMA). The collected data were part of a retrospective literature review and analysis. Thus, a written ethical approval was not obtained before commencing the study. RESULTS: Sixteen articles were found covering type-1 diabetes mellitus (DM), short stature (SS), and down syndrome (DS). Ages 1-50 years. The prevalence of seropositive-CD was 15.6% with high heterogeneity (I(2)=80.353), while prevalence of biopsy-proven CD was 10.6% with high heterogeneity (I(2)=73.359). Another article reported the CD prevalence in the at-risk population as 18.4% for the seroprevalence and 6.9% for the biopsy-proven CD. Anti-transglutaminase (anti-tTG) was used in 12 studies; in the remaining 4 studies (EMA in 2, ARA with AGA in one and no details given in one study). CONCLUSION: Both the prevalence of biopsy-proven CD (10.6%) and seroprevalence (15.6%) were higher than those we previously reported in the normal population (1.4% and 2.7%). The female-to-male ratio (1.9/1) of CD patients was the same in normal and at-risk populations in SA. Meta-analysis for prevalence of CD in DM, SS, and DS separately in SA is recommended.
format Online
Article
Text
id pubmed-6452613
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-64526132019-04-29 Celiac disease among at-risk individuals in Saudi Arabia Safi, Mohammad-Ayman A. Saudi Med J Systematic Review OBJECTIVES: To perform a meta-analysis for celiac diseases (CD) among at-risk populations in Kingdom of Saudi Arabia (KSA), as well as a comparison with our previously reported meta-analysis in the normal population. METHODS: In March 2018, at King Abdulaziz University, Jeddah, KSA we commenced a retrospective comprehensive database and journal search for CD among at-risk populations in SA. Data from each of the relevant articles were analyzed using the Statistical Package for Social Science Version 20 (Armonk, NY: IBM Corp.). and the comprehensive meta-analysis program (CMA). The collected data were part of a retrospective literature review and analysis. Thus, a written ethical approval was not obtained before commencing the study. RESULTS: Sixteen articles were found covering type-1 diabetes mellitus (DM), short stature (SS), and down syndrome (DS). Ages 1-50 years. The prevalence of seropositive-CD was 15.6% with high heterogeneity (I(2)=80.353), while prevalence of biopsy-proven CD was 10.6% with high heterogeneity (I(2)=73.359). Another article reported the CD prevalence in the at-risk population as 18.4% for the seroprevalence and 6.9% for the biopsy-proven CD. Anti-transglutaminase (anti-tTG) was used in 12 studies; in the remaining 4 studies (EMA in 2, ARA with AGA in one and no details given in one study). CONCLUSION: Both the prevalence of biopsy-proven CD (10.6%) and seroprevalence (15.6%) were higher than those we previously reported in the normal population (1.4% and 2.7%). The female-to-male ratio (1.9/1) of CD patients was the same in normal and at-risk populations in SA. Meta-analysis for prevalence of CD in DM, SS, and DS separately in SA is recommended. Saudi Medical Journal 2019-01 /pmc/articles/PMC6452613/ /pubmed/30617375 http://dx.doi.org/10.15537/smj.2019.1.23892 Text en Copyright: © Saudi Medical Journal https://creativecommons.org/licenses/by-nc-sa/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Systematic Review
Safi, Mohammad-Ayman A.
Celiac disease among at-risk individuals in Saudi Arabia
title Celiac disease among at-risk individuals in Saudi Arabia
title_full Celiac disease among at-risk individuals in Saudi Arabia
title_fullStr Celiac disease among at-risk individuals in Saudi Arabia
title_full_unstemmed Celiac disease among at-risk individuals in Saudi Arabia
title_short Celiac disease among at-risk individuals in Saudi Arabia
title_sort celiac disease among at-risk individuals in saudi arabia
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452613/
https://www.ncbi.nlm.nih.gov/pubmed/30617375
http://dx.doi.org/10.15537/smj.2019.1.23892
work_keys_str_mv AT safimohammadaymana celiacdiseaseamongatriskindividualsinsaudiarabia